LiveOpenAI Raises $11 Billion So Far at a $1.25 Trillion Valuation, Short of Its $30 Billion Goal
    WYDE
    Sign inSubscribe
    WYDE Newsroom Submit
    Impact startupHealthSeries C+

    Life Biosciences

    Life Biosciences is a biotechnology company that develops cellular rejuvenation medicines to reverse diseases of aging.

    Chief Scientific Officer
    Sharon Rosenzweig-Lipson
    Raised in the rounds listed
    $212 million
    Founders
    David Sinclair, Tristan Edwards
    Founded
    2017

    Leadership

    Sharon Rosenzweig-Lipson, Chief Scientific Officer. Sharon Rosenzweig-Lipson, Ph.D., is the Chief Scientific Officer of Life Biosciences.

    Who it reaches

    People living with optic neuropathies such as glaucoma, through the Phase 1 trial of its ER-100 therapy, with the company aiming its medicines at diseases of aging.

    Life Biosciences funding rounds

    DateRoundAmount
    Apr 8, 2026Series D$80 million
    Jan 5, 2022Series C$82 million
    Jan 15, 2019Series B$50 million

    Key facts

    Lead program
    ER-100, in development for open-angle glaucoma and NAIONsource
    Trial start
    Phase 1 clinical trial initiated in the first quarter of 2026source
    Platform
    Epigenetic Restoration platform uses OCT4, SOX2 and KLF4 (OSK)source

    WYDE coverage of Life Biosciences

    WYDE Newsroom has published 3 articles about Life Biosciences, from Jul 14, 2026 to Oct 9, 2026. Life Biosciences is the subject of 3 stories. The most recent is Life Bio's ER-100 Shows Early Vision Signals in 2 of 3 Glaucoma Patients.

    Healthcare

    Life Bio's ER-100 Shows Early Vision Signals in 2 of 3 Glaucoma Patients

    Life Biosciences reported interim Phase 1 results for ER-100, a gene therapy that delivers three genes to the eye, in three patients with open-angle glaucoma.

    Oct 9, 2026 · 3 min read · Subject of the story

    WYDE Weekly

    Visa built stablecoin rails, Wyoming set a giving record, and the EAT Card hit the App Store. Over 60,000 meals.

    WYDE Weekly: Visa's stablecoin platform, DTCC's first live tokenized trades, the Senate's unanimous no-pardon vote on SBF, WyoGives' record $6.46 million, Lilly's $100 billion endowment, and the EAT Card iOS launch.

    Jul 18, 2026 · 6 min read · Subject of the story

    Healthcare

    Life Biosciences Doses the First Patient as Cellular Rejuvenation Reaches Human Trials

    Life Biosciences dosed the first patient in its ER-100 partial epigenetic reprogramming trial and NewLimit raised $435 million for its own first human trial, moving cellular rejuvenation and longevity science from mice into people in 2026.

    Jul 14, 2026 · 2 min read · Subject of the story

    Reported alongside Life Biosciences

    Sources

    Track the institutions that move money.

    Data-driven coverage, every week.